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example, infusion reactions for ‘lower risk’ 
drugs can be clinically manageable and are 
usually of less concern than neutralizing anti-
bodies cross-reacting with endogenous pro-
teins. Nevertheless, ADAs for low-risk drugs 
can expose patients to clinical conditions that 
affect the overall benefit-risk assessment that is 
the central regulatory task before approval. The 
same holds true for a loss of efficacy by neutral-
izing antibodies. The situation is further com-
plicated by the finding of different immune 
responses to a given product in different dis-
eases and patient populations4. In other words, 
although overall a biological drug might be a 
lower-risk compound, the individual clinical 
sequelae are of high importance for the indi-
vidual patient and have an impact on overall 
regulatory benefit-risk analysis.
Some explicit recommendations by Shankar 
et al.1, such as the characterization of ADA 
positives to be explored only when considered 
necessary or decisions per clinical trial within 
a program, also pose the danger that data gen-
erated in a strategy for a predefined ‘medically 
low risk’ drug turn out to be insufficient for 
a proper benefit-risk assessment and thus do 
not meet regulatory requirements at the time 
of approval.
Thus, although many of the ideas devel-
oped by Shankar et al. have the merit of 
focusing on a risk-based approach and are 
valid and indeed interesting, we feel that their 
scheme of risk-based classification of prod-
ucts serve as a useful starting point for reflec-
tion at the time of planning immunogenicity 
studies as part of clinical trials; however, they 
may not in all cases be sufficient to support 
the benefit-risk evaluation required at the 
time of licensing of the product. Companies 
still need to justify their approach when filing 
a marketing authorization application in the 
European Union. We believe the European 
approach to immunogenicity, as presented 
in the final guideline document, retains a 
good balance by providing guidance on the 
conceptual planning of an immunogenic-
ity evaluation on one hand, but being suf-
ficiently open-minded to allow the flexibility 
needed for ‘individual’ biological drugs, on 
the other hand.
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Reflect: augmented browsing for 
the life scientist
To the Editor:
Anyone who regularly reads life science litera-
ture often comes across names of genes, pro-
teins or small molecules that they would like to 
know more about. To make this process easier, 
we have developed a new, free service called 
Reflect (http://reflect.ws) that can be installed 
as a plug-in to web browsers, such as Firefox or 
Internet Explorer. Reflect tags gene, protein and 
small-molecule names in any web page, typi-
cally within a few seconds and without affecting 
document layout. Clicking on a tagged gene or 
protein name opens a popup showing a concise 
summary that includes synonyms, database 
identifiers, sequence, domains, three-dimen-
sional structure, interaction partners, subcellu-
lar location and related literature. Clicking on 
a tagged small-molecule name opens a popup 
showing two-dimensional structure and inter-
action partners. The popups also allow naviga-
tion to commonly used databases. In the future, 
we plan to add further entity types to Reflect, 
including those outside the life sciences.
As science uncovers the intricate intercon-
nections within biological systems, many life 
scientists constantly come across unfamiliar bio-
chemical entities (e.g., genes, proteins or small 
molecules) that were previously not known to be 
relevant to a given field, but where today’s litera-
ture shows an important, new connection. For 
such cases, it is clearly valuable to systematically 
tag all scientific entities in a publication, thus 
helping the reader to navigate to more specific 
information about any entity of interest. Such 
tags can help the reader to comprehend scien-
tific content more rapidly and completely. Even 
when an entity is already familiar to a reader, 
it can be valuable to have quick access to com-
monly used source data entries; for example, 
protein sequences or two-dimensional struc-
tures of small molecules.
In spite of the clear value of systematically 
tagging scientific entities, only a small fraction 
of the main scientific publishers currently offer 
such tags on their web content. Some publishers 
are beginning to explore the option of adding 
tags as part of the publication process1; how-
ever, enforcing, validating and updating these 
tags creates additional work for publishers and 
authors.
The task of accurately tagging biochemical 
entities automatically is very challenging; this 
task has been the subject of intense research 
efforts that has led to significant improvements 
in accuracy2. These automated methods have 
been used to develop a wide variety of text min-
ing applications and services, many of which are 
designed to provide sophisticated search, anal-
ysis and presentation capabilities3. However, a 
few text mining services have been designed to 
appeal to the broader life science community; for 
example, iHOP4 provides simple search, naviga-
tion and presentation of Medline abstracts with 
systematically tagged gene and protein names.
Tagging a scientific entity is only half the 
story: the other half is the information that is 
accessed when the user clicks on a tag. In the 
past, entity tags were almost always simple 
hyperlinks to web pages showing source data 
entries. Increasingly, however, entity tags are 
not hyperlinks but scripts that create a small 
popup window (typically with Javascript). A key 
advantage of using popups is that users can see 
basic information about an entity without hav-
ing to navigate away from the current web page. 
If needed, hyperlinks to more detailed informa-
tion can be provided on the popup.
An emerging trend is to augment nor-
mal web browsing by using plug-ins, such as 
Greasemonkey (http://greasespot.net/), that let 
end-users modify the appearance of web pages 
while browsing. We believe that such augmented 
browsing tools will soon have an important 
impact on how scientists read literature on the 
web. For example, one such tool, ChemGM5, 
lets end-users tag small-molecule names in any 
web page; clicking on a tagged small molecule 
opens a popup that shows the two-dimensional 
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structure. Tagging is done by sending the page 
to a remote server, and the total time taken is 
typically about one minute for a five-page docu-
ment. Another tool, Concept Web Linker (http://
conceptweblinker.wikiprofessional.org/), has a 
broader scope: it tags a range of entities, such 
as genes, chemicals and diseases, again typically 
within about one minute. However, the Concept 
Web Linker popups show less specific informa-
tion, giving only a short text description for each 
entity; to reach more specific information, such 
as protein sequences, the user needs to navigate 
through a series of web pages, in some cases 
browsing complex ontologies. A related system, 
Cohse6, has even broader scope—it enables users 
to choose many different ontologies, including 
those outside the life sciences. Currently, how-
ever, the publicly accessible versions of Cohse 
provide only very limited functionality and 
using the life-science ontologies provided does 
not allow direct navigation to specific informa-
tion, such as sequences.
We designed Reflect to be an augmented 
browsing tool that would be broadly useful to 
life scientists, and would address the limitations 
of the above tools. A primary goal of Reflect was 
to enable the user to navigate directly from a 
gene or protein name to a specific sequence. A 
second goal was to be able to tag a typical web 
page in a few seconds. A third goal was to pro-
vide entity popups that give a concise summary 
of the most important features of the entities, 
as well as direct hyperlinks to commonly used 
source data entries (Fig. 1 and Supplementary 
Methods online). Finally, Reflect was designed 
with a strong focus on ease of installation and 
on usability.
Reflect can be used directly from http://reflect.
ws/ by typing or pasting in a URL. In this case, 
the Reflect server retrieves the HTML docu-
ment, tags it and returns the tagged version to 
the user’s browser. Note that this will work only 
for URLs that are publicly accessible.
A more convenient way to use Reflect is 
to install it as a plug-in to Firefox or Internet 
Explorer. In this case, the HTML document 
is retrieved by the user’s browser, then sent 
to the Reflect server, tagged and returned to 
the browser. Thus, with the plug-in, users can 
‘Reflect’ any page that they can access.
The Reflect server at the European Molecular 
Biology Laboratory keeps in RAM (random-
access memory) a large dictionary with names 
and synonyms for 4.3 million small molecules, 
and for 1.5 million proteins from 373 organ-
isms. When tagging an HTML document, the 
server finds all occurrences of these synonyms 
and returns a slightly modified version of the 
HTML document to the user’s browser—the 
only difference is that all matching protein, gene 
and small-molecule names are now tagged and 
highlighted. Tagging a document usually takes 
much less time than uploading and download-
ing it; thus, the time taken for the entire process 
(upload, tag and download) depends almost 
exclusively on the speed of the user’s internet 
connection. With standard broadband, the 
entire process usually takes from one to five sec-
onds for a five-page document (Supplementary 
Methods).
Clicking on a tagged small-molecule name 
opens a summary popup (Fig. 1, bottom right) 
that shows two-dimensional structures from 
PubChem7 and interaction partners from 
STITCH8. Clicking on a tagged protein or gene 
name opens a popup (Fig. 1, top right) that 
shows synonyms, the complete amino acid 
sequence of the longest transcript, domains 
from the SMART9 database, a representative 
three-dimensional structure from PDBsum10, 
principal interaction partners from STITCH8, 
known subcellular location and an image of the 
organism. Most of these features on the popup 
are hyperlinked to related database entries. The 
popup also has hyperlinks to the correspond-
ing gene entry and to related Medline abstracts 
in iHOP4. Dragging the mouse on the domain 
graphical view scrolls through the sequence, 
and hovering over a domain causes the domain 
name to appear in a tool tip.
When a tagged name is ambiguous, the popup 
shows all possible matches and allows the user 
to disambiguate the name by choosing which of 
the possibilities is most appropriate. Currently, 
three levels of ambiguity are shown. First, a name 
may match both a protein and a small molecule; 
in this case, Reflect shows both possibilities on 
separate tabs. Second, a name may match to 
several genes within the same organism; here, 
Reflect shows all matching genes in a pull-down 
menu. And third, for gene and protein names, it 
is often ambiguous which organism is intended 
in the HTML document; to address this, Reflect 
shows a list of possible organisms derived from 
the default organism (which is initially set to 
human, but can be changed using the Firefox 
plug-in) plus organisms mentioned in the docu-
ment. In the near future, we also plan to show 
a fourth level of ambiguity, where users will be 
able to select splice variants for each gene.
Any automated method for recognizing 
biochemical entity names will make some 
errors: some false positive matches will arise 
due to overlap with commonly used words or 
acronyms, and false negatives will arise due to 
incompleteness of the tagging dictionary. To 
assess the accuracy of Reflect, we tested it against 
the BioCreative11 benchmarks. Compared with 
15 other tools for automated entity recogni-
tion that were assessed in BioCreative, Reflect 
ranked second best (91% F-score) using the 
Saccharomyces cerevisiae benchmark and had 
median performance (66% F-score) using the 
Drosophila melanogaster benchmark. We con-
sider these to be quite good results because, 
unlike the other tools tested against these bench-
marks, Reflect was designed to optimize speed 
rather than accuracy.
In the near future, we plan to enable com-
munity-based, collaborative editing for some 
of the information in Reflect popup, especially 
the synonym lists. These and other planned 
extensions will enable the user community to 
improve Reflect by correcting false-negative and 
false-positive matches. We plan to add further 
Figure 1  The Reflect button can be installed in the Firefox or Internet explorer web browsers. clicking the 
Reflect button tags protein and gene names (blue highlighting), and small molecules (orange highlighting) 
in any web page. clicking on a highlighted name opens a small popup showing a concise summary of 
important features of the entity, and provides access to related information (Supplementary Methods).
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Note: Supplementary information is available on the 
Nature Biotechnology website.
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entity types (e.g., diseases, pathways and organ-
isms), and eventually to add entity types beyond 
the life sciences; we designed Reflect to be an 
extendible platform, and we welcome collabora-
tion proposals for adding further entity types. In 
addition, we welcome proposals from publishers 
and data providers interested in programmatic 
access to Reflect. With such access, end-users can 
use ‘Reflected’ content without needing to install 
a browser plug-in.
In summary, Reflect creates a view of the web 
tailored for the life scientist, that is, with system-
atic tagging of biochemical entities, and easy 
access to more detailed information. Reflect is 
already being used by thousands of researchers, 
and we have received much positive feedback 
regarding Reflect’s usefulness and ease of use. 
In addition, just before publication of this cor-
respondence, Reflect was awarded first prize in 
the Elsevier Grand Challenge, a contest for tools 
that improve the way scientific information is 
communicated. Thus, we believe that Reflect 
can be a valuable tool for researchers, teachers, 
students and anyone who reads life science lit-
erature on the web. We further predict that in 
the near future tools such as Reflect will change 
dramatically how scientists use the web.
Extrapolating from sequence—the 
2009 H1N1 ‘swine’ influenza virus
Sharing Avian Influenza Data; http://platform.
gisaid.org/) and the NCBI Influenza Virus 
Resource (National Center for Biotechnology 
Information; http://www.ncbi.nlm.nih.gov/
genomes/FLU/FLU.html). Comparison of the 
amino acid sequences between the 38 isolates 
showed some intragenic differences: seven 
amino acid positions in HA (hemagglutinin), 
one in M1 (matrix 1), two in M2 (matrix 2), four 
in NA (neuraminidase), three in NP (nucleopro-
tein), two in PA and two in PB2 (both of which 
encode subunits of viral RNA polymerase). 
Given the few intragenic variations among the 
38 isolates available at the time of this study, we 
use /California/04/2009 (Cal0409) as a represen-
tative 2009 H1N1 virus strain for further analy-
sis. The top ranking hits of the BLAST search 
using the individual Cal0409 genes are shown 
in Supplementary Table 1 online.
Comparison of Cal0409 HA with the HA 
consensus sequences for human-adapted 
H1N1, avian-adapted H1N1 and swine-
adapted H1N1 reveals important substitu-
tions in positions 100–300, where the glycan 
receptor-binding sites and antigenic loops 
are located (Supplementary Table 2 online). 
Notably, the Cal0409 HA possesses the signa-
ture amino acids Asp190 and Asp225 that have 
been shown to play a key role in conferring 
specificity to the human α2-6 sialylated glycan 
receptors1. We also observe amino acid sub-
stitutions that are unique to Cal0409 HA and 
have not been observed in previous human 
H1N1 HAs. These include substitutions at 
sequence positions 74, 131, 145, 208, 219, 261, 
263, 264, 305, 317, 368, 377 and 530. Among 
these residue positions, 131 and 145 are proxi-
mal to the glycan-binding site.
To determine the possible effect of these 
mutations on the glycan-binding properties 
of HA, we constructed homology-based struc-
tural complexes of Cal0409 with representative 
α2-3 and α2-6 sialylated oligosaccharides, as 
described earlier8 (Fig. 1). The construction 
of theoretical HA-glycan structural complexes 
previously8 allowed us to provide a structural 
rationale for how specific amino acid muta-
tions within the 1918 H1N1 HA can dramati-
cally alter its relative α2-3/α2-6 binding affinity. 
Referencing these previous efforts, we deter-
mined the potential glycan binding properties 
of Cal0409 HA by analyzing its contacts with 
the α2-3 and α2-6 sialylated glycans.
On the basis of the observed contacts in the 
HA-glycan complexes, we summarize in Table 1 
the proposed roles of the residues in Cal0409 
HA that provide binding specificity to α2-3 
and α2-6 oligosaccharides, respectively. The 
main differences between the glycan-binding 
pockets of reference HAs and Cal0409 HA lie 
in the 140-loop region and the loop region pre-
ceding the 190-helix. Lys145, which is unique to 
Cal0409, along with Lys133 and Lys222, form a 
positively charged ‘lysine fence’ at the base of the 
binding site that potentially are positioned to 
anchor the N-acetylneuraminic acid (Neu5Ac) 
and galactose (Gal) sugars of both α2-3 and 
α2-6 glycans. In the case of the Cal0409 α2-6 
oligosaccharide structural complex, the lysine 
fence also includes Lys156, which is positioned 
to provide additional contact with the glycan. 
The orientation of Asp190 is typically stabilized 
by a network of interactions involving residues 
at 186, 187 and 189 that precede the 190-helix. 
In Cal0409 HA, the residues at these positions 
are Ser186, Thr187 and Ala189; this set of resi-
dues is unique to the 2009 H1N1 strains. These 
residues appear to retain the ability to stabilize 
the orientation of Asp190 such that it is posi-
tioned to make optimal contacts with the third 
N-acetylglucosamine (GlcNAc) sugar (starting 
from Neu5Ac toward the reducing end) of α2-6 
glycans, defined previously8.
Our observations of the Cal0409 HA–glycan 
interactions suggest that this HA has the nec-
essary residues to provide optimal contacts for 
To the Editor:
The recent incidence and spread in humans of 
the ‘swine flu’ influenza A virus has raised global 
concerns regarding its virulence and pandemic 
potential. The main cause of the so-called swine 
flu has been identified as human infection by 
influenza A viruses of a new H1N1 (hemag-
glutinin 1, neuraminidase 1) subtype, or ‘2009 
H1N1 strain’. The first cases of human infection 
were reported in April in the Mexican town of 
La Gloria in Veracruz; soon after, reported infec-
tions occurred in areas of southern California 
and Texas. Several recent studies have focused 
on the necessary determinants for human adap-
tation and efficient human-to-human transmis-
sion of the H1N1 influenza A viruses1–9. Here, 
using a representative 2009 H1N1 strain as our 
starting point, we offer a perspective on the 
likely human adaptation and transmissibility 
of 2009 H1N1 viruses.
At the time when this sequence analysis was 
performed, partial or complete sequences were 
available from 38 different human isolates of 
the 2009 H1N1 virus. These sequences were 
obtained from GISAID (Global Initiative on 
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